

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Page 1 of 1

PATENT NO. : 11,672,803
APPLICATION NO. : 16/926,280
ISSUE DATE : June 13, 2023
INVENTOR(S) : Joseph J. Buggy

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the cover page, after the first inventor, please add the following inventors:

-- Lee Honigberg, San Francisco, CA (US); David J. Loury, Incline Village, NV (US); Ahmed Hamdy, Santa Cruz, CA (US) --

MAILING ADDRESS OF SENDER (Please do not use Customer Number below):

Hathaway P. Russell
FOLEY HOAG LLP
155 Seaport Boulevard
Boston, Massachusetts 02210-2600

Docket No.: PIR-81970
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of:
Joseph J. Buggy

Patent No.: 11,672,803

Issued: June 13, 2023

For: USE OF INHIBITORS OF BRUTONS
TYROSINE KINASE (BTK)

REQUEST FOR CERTIFICATE OF CORRECTION
PURSUANT TO 37 C.F.R. § 1.323

Attention: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

This Request for Certificate of Correction has been filed along with a Request for Correction of Inventorship under 37 C.F.R. § 1.324.

Upon reviewing the above-identified patent, Patentee noted through error that inventors were not named, which should be corrected.

Specifically, under item “(72) Inventor” on the cover page, please add the following inventors after the first inventor:

-- Lee Honigberg, San Francisco, CA (US); David J. Loury, Incline Village, NV (US); Ahmed Hamdy, Santa Cruz, CA (US) --

The error was found in the application as filed by Applicant.

The error now sought to be corrected is an error the correction of which does not involve new matter or require reexamination.

Transmitted herewith is a proposed Certificate of Correction effecting such amendment. Patentee respectfully solicits the granting of the requested Certificate of Correction.

Please charge our **Deposit Account No. 06-1448** in the amount of \$160.00 covering the fee set forth in 37 C.F.R. § 1.20(a). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Deposit Account No. 06-1448, under Order No. PIR-81970**.

Dated: July 15, 2024

Respectfully submitted,

Electronic signature: */Hathaway Russell /*

Hathaway P. Russell

Registration No.: 46,488

FOLEY HOAG LLP

155 Seaport Boulevard

Boston, Massachusetts 02210-2600

(617) 832-1286

Attorney For Applicant

Docket No.: PIR-81970
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 16/926,280
Filing Date: July 10, 2020
Patent No.: 11,672,803
First Inventor: Joseph J. BUGGY
Attorney No.: PIR-81970
Confirmation No.: 3851
Examiner: Ramachandran, Umamaheswari
For: USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)

STATEMENT TO CORRECT INVENTORSHIP UNDER 37 C.F.R. §1.324(b)(1)


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:


I, **Ahmed HAMDY**, hereby state that: (1) I agree to the correction of inventorship of the above-referenced patent through the addition of **Ahmed HAMDY**, **David LOURY**, and **Lee HONIGBERG** as co-inventors, as requested in the accompanying Request to Correct Inventorship; or (2) I have no disagreement in regard to the accompanying Request to Correct Inventorship.

DATED this 21 day of May, 2024

Signature:



Printed Name:



Docket No.: PIR-81970
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 16/926,280
Filing Date: July 10, 2020
Patent No.: 11,672,803
First Inventor: Joseph J. BUGGY
Attorney No.: PIR-81970
Confirmation No.: 3851
Examiner: RAMACHANDRAN, Umamaheswari
For: USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)

STATEMENT TO CORRECT INVENTORSHIP UNDER 37 C.F.R. § 1.324(b)(2)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

Pharmacyclics LLC—the assignee of the entire right, title, and interest of the above-identified patent by recordations on February 8, 2023, at Reel/Frame 062632/0667; on March 14, 2023, at Reel/Frame 062977/0071; on March 14, 2023, at Reel/Frame 062976/0972, in the United States Patent and Trademark Office; and in the assignments included herewith from Lee Honigberg, David J. Loury, and Ahmed Hamdy — hereby consents to the correction of the inventorship of U.S. Patent Number 11,672,803, as requested by the accompanying papers.

I have authority and hereby give this consent on behalf of Pharmacyclics LLC.

DATED this 15th day of July, 20224

Signature: / Hathaway Russell /

Printed Name: Hathaway Russell

Title: Attorney of Record



ELECTRONIC PAYMENT RECEIPT

APPLICATION #
16/926,280

RECEIPT DATE / TIME
07/15/2024 07:06:24 PM Z ET

ATTORNEY DOCKET #
PIR-81970

Title of Invention

USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)

Application Information

APPLICATION TYPE Utility - Nonprovisional Application
under 35 USC 111(a)

PATENT # 11672803

CONFIRMATION # 3851

FILED BY Kathryn Dunn

PATENT CENTER # 66374725

AUTHORIZED BY Hathaway Russell

CUSTOMER # 136314

FILING DATE 07/10/2020

CORRESPONDENCE ADDRESS -

FIRST NAMED INVENTOR Joseph J. Buggy

Payment Information

PAYMENT METHOD
DA / 061448

PAYMENT TRANSACTION ID
E20247EJ07117028

PAYMENT AUTHORIZED BY
Hathaway Russell

PRE-AUTHORIZED ACCOUNT
061448

PRE-AUTHORIZED CATEGORY
37 CFR 1.16 (National application filing, search, and examination fees); 37 CFR 1.17 (Patent application and reexamination processing fees); 37 CFR 1.19 (Document supply fees); 37 CFR 1.20 (Post issuance fees); 37 CFR 1.21 (Miscellaneous fees and charges)

FEE CODE	DESCRIPTION	ITEM PRICE(\$)	QUANTITY	ITEM TOTAL(\$)
1830	PROCESSING FEE, EXCEPT IN PROVISIONAL APPLICATIONS	140.00	1	140.00
1819	CORRECTION OF INVENTORSHIP AFTER FIRST ACTION ON MERITS	640.00	1	640.00
TOTAL AMOUNT:				\$780.00

by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.



UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #
16/926,280

RECEIPT DATE / TIME
07/15/2024 07:06:24 PM Z ET

ATTORNEY DOCKET #
PIR-81970

Title of Invention

USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)

Application Information

APPLICATION TYPE Utility - Nonprovisional Application
under 35 USC 111(a)

PATENT # 11672803

CONFIRMATION # 3851

FILED BY Kathryn Dunn

PATENT CENTER # 66374725

FILING DATE 07/10/2020

CUSTOMER # 136314

FIRST NAMED INVENTOR Joseph J. Buggy

CORRESPONDENCE ADDRESS -

AUTHORIZED BY Hathaway Russell

Documents

TOTAL DOCUMENTS: 10

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
PIR-81970_Statement_to_Correct_Inventorship.pdf	1	Miscellaneous Incoming Letter	16 KB
PIR-81970_Req_COC.pdf	2	Request for Certificate of Correction	24 KB
PIR-81970_Certificate_of_Correction.pdf	1	Request for Certificate of Correction	19 KB
PIR-81970_Buggy_Statement_to_Correct_Inventorship.pdf	1	Miscellaneous Incoming Letter	87 KB

PIR- 81970_Hamdy_Statement_to _Correct_Inventorship.pdf	1	Miscellaneous Incoming Letter	293 KB
PIR- 81970_Honigberg_Statement _to_Correct_Inventorship.pdf	2	Miscellaneous Incoming Letter	372 KB
PIR- 81970_Loury_Statement_to_ Correct_Inventorship.pdf	1	Miscellaneous Incoming Letter	434 KB
PIR- 81970_Req_for_Correction_o f_Inventorship.pdf	3	Miscellaneous Incoming Letter	26 KB
PIR- 81970_Statement_to_Correct _Inventorship_PIR.pdf	1	Miscellaneous Incoming Letter	210 KB
PIR- 81970_373_Statement_with_ assignments.pdf	10	Assignee showing of ownership per 37 CFR 3.73	1155 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
PIR- 81970_Statement_to_Correct_I nventorship.pdf	D880EE08910D658E05904446F07A71AE25C4A3C7A23454145F 22353B29CABA0007E183B4029D8D24CA1C5453FD2DF6D6E55 DCA467830CC3636AF40077ACA2A05
PIR-81970_Req_COC.pdf	89CC6AB4007406766D708CE860310BA959316164A15C82E7D2 6EB8DC7CC06ED73253EC84CEF6DF3627188C37C3F2A33B19 23170A3B5A362D3F368AEE2CE67483
PIR- 81970_Certificate_of_Correctio	FBBBD859270C438AD9863FEA1A5DE7691AAF82A126C8C4EE E32FCF8B27AE855424A91D88520BA41DAD3D39D9477541B4F

n.pdf	9C755889CCF7D7333C352B2576A486E
PIR- 81970_Buggy_Statement_to_C orrect_Inventorship.pdf	A6E7D6B59B7E945653E3642A73BC2FCC4C1E4D1CDDAF7D47 56728939C8B38E9CE21BEAB6975137D693A630F31D2FF65170 D818A19DDE9766C8232C23C815C87A
PIR- 81970_Hamdy_Statement_to_C orrect_Inventorship.pdf	EACEEC74648DDA54BCD21D450284614C624031984A219BC2 B642EB0B28AEC32DA749DD3506AB41A0D579AFED16DDEC3 AA114E5D96DB7B5A25C6F8EB04F0909EA
PIR- 81970_Honigberg_Statement_t o_Correct_Inventorship.pdf	ACF4BCCA937E37F5F9726B3F6F4F06F8393E0FC7DC3195F62 0810DA2D6234B4BBFF2B939B666D25DE5E5B756593D3D7B06 9FAC3A31FEC4169324BE938929A081
PIR- 81970_Loury_Statement_to_Co rrect_Inventorship.pdf	23E080D02A9401EC6EBD4EEB733193482522023C92669EBFC 8C857802BB051A9D246D76A64443DAEFB024AB3D9248DD704 3FCE237BBE693671B34BB0DA2AF01C
PIR- 81970_Req_for_Correction_of_I nventorship.pdf	7359C22D4271E660680E5F1E0479DB81285CCBE03C6A63F54 E11E35F361A5B976C518E32766C96C672F4F022F6A1DC5C714 C9BF209461AF3A585B0230640647B
PIR- 81970_Statement_to_Correct_I nventorship_PIR.pdf	08E7E41F9F165D60807B8F627B6DCAB5B43B4193E7EC5E545 C2063C0B3DAE1C1F0ABD0FEC8DE359B90F0AF642F1F94AF2 22A14EE393F7AADD87E5AE23BE103C7
PIR- 81970_373_Statement_with_as signments.pdf	CFFFE80A9E101D52640D9DEABEC36157B679FE5E9E0BA936 9EFF1656AF38460DF38BA9521C5013E1555FC5253150362CEB 9D19EFAE05C5B8337F02BB89E19472

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 16/926,280
Filing Date: July 10, 2020
Patent No.: 11,672,803
First Inventor: Joseph J. BUGGY
Attorney No.: PIR-81970
Confirmation No.: 3851
Examiner: RAMACHANDRAN, Umamaheswari
For: USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)

STATEMENT TO CORRECT INVENTORSHIP UNDER 37 C.F.R. § 1.324(b)(2)


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

Pharmacyclics LLC—the assignee of the entire right, title, and interest of the above-identified patent by recordings on February 8, 2023, at Reel/Frame 062632/0667; on March 14, 2023, at Reel/Frame 062977/0071; and on March 14, 2023, at Reel/Frame 062976/0972, in the United States Patent and Trademark Office—hereby consents to the correction of the inventorship of U.S. Patent Number 11,672,803, as requested by the accompanying papers.

I have authority and hereby give this consent on behalf of Pharmacyclics LLC.

DATED this 30th day of MAY, 2024

Signature: 

Printed Name: Johanna M. Corbin

Title: Senior Vice President, Chief Patent and Innovation Counsel

Docket No.: PIR-81970
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 16/926,280
Filing Date: July 10, 2020
Patent No.: 11,672,803
First Inventor: Joseph J. BUGGY
Attorney No.: PIR-81970
Confirmation No.: 3851
Examiner: Ramachandran, Umamaheswari
For: USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)


STATEMENT TO CORRECT INVENTORSHIP UNDER 37 C.F.R. §1.324(b)(1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

I, **David J. LOURY**, hereby state that: (1) I agree to the correction of inventorship of the above-referenced patent through the addition of **David J. LOURY**, **Lee HONIGBERG** and **Ahmed HAMDY** as co-inventors, as requested in the accompanying Request to Correct Inventorship; or (2) I have no disagreement in regard to the accompanying Request to Correct Inventorship.

DATED this 19th day of April, 2024

Signature: 

Printed Name: David J. Loury

Docket No.: PIR-81970
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 16/926,280
Filing Date: July 10, 2020
Patent No.: 11,672,803
First Inventor: Joseph J. BUGGY
Attorney No.: PIR-81970
Confirmation No.: 3851
Examiner: Ramachandran, Umamaheswari
For: USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)

STATEMENT TO CORRECT INVENTORSHIP UNDER 37 C.F.R. §1.324(b)(1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

I, **Lee HONIGBERG**, hereby state that: (1) I agree to the correction of inventorship of the above-referenced patent through the addition of **Lee HONIGBERG, David J. LOURY** and **Ahmed HAMDY** as co-inventors, as requested in the accompanying Request to Correct Inventorship; or (2) I have no disagreement in regard to the accompanying Request to Correct Inventorship.

DATED this 26 day of April, 2024

A handwritten signature in black ink, appearing to read "Lee Honigberg", is written over a horizontal line.

Signature: _____

Printed Name: _____ Lee Honigberg _____

Docket No.: PIR-81970
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 16/926,280
Filing Date: July 10, 2020
Patent No.: 11,672,803
First Inventor: Joseph J. BUGGY
Attorney No.: PIR-81970
Confirmation No.: 3851
Examiner: RAMACHANDRAN, Umamaheswari
Art Unit: 1627
For: USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)

**REQUEST FOR CORRECTION OF INVENTORSHIP IN PATENT
UNDER 37 C.F.R. § 1.324**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

The Patentee respectfully requests that the inventorship of the above-captioned patent be corrected to add **Lee HONIGBERG, David J. LOURY, and Ahmed HAMDY** as joint inventors. The inventive entity in U.S. Patent No. 11,672,803 was set forth in error. In support of this request, the following documents are enclosed:

1. A Statement regarding the change of inventorship by the newly named joint inventor, Lee HONIGBERG under 37 CFR § 1.324(b)(1).

2. A Statement regarding the change of inventorship by the newly named joint inventor, David J. LOURY under 37 CFR § 1.324(b)(1).
3. A Statement regarding the change of inventorship by the newly named joint inventor, Ahmed HAMDY under 37 CFR § 1.324(b)(1).
4. A Statement regarding the change of inventorship by the named inventor, Joseph J. BUGGY, under 37 CFR § 1.324(b)(1).
5. A Statement under 37 CFR §1.324(b)(2) from the assignee, Pharmacyclics LLC, regarding the change of inventorship, and establishing ownership by reference to recorded assignments from the current inventors.
6. A Statement under 37 C.F.R. § 3.73(c) referencing the chain of recorded assignments from the inventors to the assignee, Pharmacyclics LLC.
7. A Request for Certificate of Correction under 37 C.F.R. §1.323.
8. A Certificate of Correction.
9. The fee set forth in 37 C.F.R. § 1.20(a).
10. The fee set forth in 37 C.F.R. § 1.20(b).

Patentee does not believe that any additional fees are required. Should any additional fees be required for timely consideration of the present Petition, however, Patentee hereby petitions for same and request that the required fees be charged to **Deposit Account No. 06-1448, Att. Ref. No.: PIR-81970.**

If any issues remain that may be resolved by telephone or facsimile communication with the Patentee's attorney, the Office is invited to contact the undersigned at the numbers shown below.

Dated: July 15, 2024

Respectfully submitted,

Electronic signature: */Hathaway Russell /*

Hathaway P. Russell

Registration No.: 46,488

FOLEY HOAG LLP

155 Seaport Boulevard

Boston, Massachusetts 02210-2600

(617) 832-1286

Attorney For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(c)

Applicant/Patent Owner: Pharmacyclics LLC

Application No./Patent No.: 11,672,803 Filed/Issue Date: June 13, 2023

Titled: USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)

Pharmacyclics LLC, a Limited Liability Company
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that, for the patent application/patent identified above, it is (choose **one** of options 1, 2, 3 or 4 below):

1. ☒ The assignee of the entire right, title, and interest.
2. ☐ An assignee of less than the entire right, title, and interest (check applicable box):
- ☐ The extent (by percentage) of its ownership interest is _____ %. Additional Statement(s) by the owners holding the balance of the interest must be submitted to account for 100% of the ownership interest.
- ☐ There are unspecified percentages of ownership. The other parties, including inventors, who together own the entire right, title and interest are:

Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest.

3. ☐ The assignee of an undivided interest in the entirety (a complete assignment from one of the joint inventors was made). The other parties, including inventors, who together own the entire right, title, and interest are:

Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest.

4. ☐ The recipient, via a court proceeding or the like (e.g., bankruptcy, probate), of an undivided interest in the entirety (a complete transfer of ownership interest was made). The certified document(s) showing the transfer is attached.

The interest identified in option 1, 2 or 3 above (not option 4) is evidenced by either (choose **one** of options A or B below):

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Joseph Buggy To: Pharmacyclics, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 062632, Frame 0667, or for which a copy thereof is attached.
Oxford Amherst Corporation
2. From: Pharmacyclics, Inc. To: Pharmacyclics, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 062977, Frame 0071

STATEMENT UNDER 37 CFR 3.73(c)

- Pharmacyclics, Inc.
3. From: Oxford Amherst LLC To: Pharmacyclics LLC
 The document was recorded in the United States Patent and Trademark Office at
 Reel 062976 , Frame 0972
4. From: Lee Honigberg To: Pharmacyclics LLC
 The document was recorded in the United States Patent and Trademark Office at
 Reel _____ , Frame _____
5. From: David J. Loury To: Pharmacyclics Inc.
 The document was recorded in the United States Patent and Trademark Office at
 Reel _____ , Frame _____ , or for which a copy thereof is attached.
6. From: Ahmed Hamdy To: Pharmacyclics LLC
 The document was recorded in the United States Patent and Trademark Office at
 Reel _____ , Frame _____ , or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet(s).

☒ As required by 37 CFR 3.73(c)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

 Signature / Hathaway Russell /

 Date July 15, 2024

 Printed or Typed Name Hathaway P. Russell

 Title or Registration Number 46,488

ASSIGNMENT

WHEREAS I, Lee HONIGBERG of San Francisco, California hereinafter the "Assignor", have made certain new and useful inventions as described in:

United States Patent Application No. 15/965,114, filed on April 27, 2018 entitled "USE OF INHIBITORS OF BRUTONS TYRSINE KINASE (BTK)" {Atty. Docket No. PIR-81918};

WHEREAS, Pharmacyclics LLC, a Limited Liability Company organized and existing under the laws of Delaware having a place of business at 995 E. Arques Avenue, Sunnyvale, CA 94085 hereinafter the "Assignee", desires to acquire the entire right, title and interest in and to the inventions and the patent application(s) identified above, and all patents, foreign and domestic, which may be obtained for said inventions, and Assignor desires to assign such rights to Pharmacyclics LLC, as set forth below;

NOW, THEREFORE, in exchange for valuable and legally sufficient consideration, the receipt of which is hereby acknowledged:


1. The Assignor has sold, conveyed, assigned and transferred, and by these presents does sell, convey, assign and transfer, to the Assignee their entire right, title and interest for the United States and all other jurisdictions in and to the inventions and the patent application(s) identified above, and any patents that may issue for said inventions, together with all patent applications, patents, utility models and designs therefore, including without limitation all continuations, divisions, renewals, revivals, reissues, reexaminations, extensions, supplementary protection certificates, and any substitute applications thereof, including the full right to claim all benefits and priority rights thereto under any applicable convention or treaty including without limitation the Paris Convention, and all rights of action arising from the foregoing, including without limitation all claims for damages by reason of present, past and future infringement or violation of the foregoing and all present, past and future rights to sue and collect damages or seek injunctive relief for any such infringement or violation of the foregoing, in each case, to have and to hold for sole and exclusive use and benefit of the Assignee, its successors and assigns.

2. The Assignor hereby covenants and agrees that Assignor has the full right to convey the interests granted by this Assignment; and that the Assignor will assist the Assignee (including prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by Assignee) in the prosecution of the patent applications identified above, in the making and prosecution of any other applications that the Assignee may elect to make covering the inventions identified above, in vesting in the Assignee with exclusive title in and to all such other patent applications and patents, in the prosecution of any interference which may arise involving said invention, or any such patent application or patent, and in assisting Assignee in the defense and enforcement of any rights arising out of such patent application or patent, or this Assignment; and that the Assignor will execute and deliver to the Assignee any and all additional papers which may be requested by the Assignee to carry out the terms of this Assignment.

3. The terms and covenants of this Assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor and their heirs, legal representatives and assigns.

IN WITNESS WHEREOF, the Assignor has executed this Assignment.


Lee HONIGBERG


Date

PATENT ASSIGNMENT

Docket Number 25922-819.201

WHEREAS, the undersigned:

- | | | | |
|--|--|---|--|
| 1. Buggy, Joseph J.
858 Cuesta Drive
Mountain View, CA 94040 | 2. Elias, Laurence
41 Alvarado Road
Berkeley, CA 94705 | 3. Fyle, Gwen
20 La Ferrara Terrace
San Francisco, CA 94133 | 4. Hedrick, Eric
59 Hobart Avenue
Summit, NJ 07901 |
| 5. Loury, David J.
7130 Galli Drive
San Jose, CA 95129 | 6. Mody, Tarak D.
955 La Mesa Terrace #E
Sunnyvale, CA 94086 | | |

(hereinafter "inventor(s)," have invented certain new and useful improvements in

THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)






- ☐ for which a United States patent application is executed on even date herewith;
☒ for which Application No. 13/153,317 was filed on June 3, 2011 in the United States Patent Office;
☐ for which Application No. _____ was filed on _____ in the U.S. Receiving Office of the Patent Cooperation Treaty;
☐ for which Application No. _____ was filed on _____ in the _____ Patent Office; and/or
☐ for which an application was filed upon which a United States Patent issued on _____ as U.S. Patent No. _____

(hereinafter "Application(s)").

WHEREAS, Pharmacyclics, Inc., a corporation of the State of Delaware, having a place of business at 995 East Arques Avenue, Sunnyvale, CA 94085, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s) and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said inventor(s) (hereinafter collectively referred to as "inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said inventor(s) to have been received in full from said Assignee:

- Said inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said inventions and said Applications, including the right to claim priority to said inventions and said Applications; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); and (d) in and to each and every reissue, reexamination, or extensions of any of said Patent(s).
- Said inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said inventions; and (f) for legal proceedings involving said inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said inventor(s) in providing such cooperation shall be paid for by said Assignee.
- The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said inventor(s), their respective heirs, legal representatives and assigns.
- Said inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
- Said inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

PATENT ASSIGNMENT		Docket Number 25922-819.201
6 This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement. IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:		
Date: <u>9-21-11</u>	 Joseph J. Buggy	Date: <u>9/16/11</u>  Laurence Elias
Date: <u>11/20/11</u>	 Owen Fyfe	Date: <u>9/20/11</u>  Erik Hedrick
Date: <u>15 Sept 2011</u>	 David J. Loury	Date: <u>9/16/11</u>  Sarah D. Mody
RECEIVED AND AGREED TO BY ASSIGNEE: Pharmacyclies, Inc. Date: <u>15 Sept 2011</u> By:  Name: <u>David J. Loury, Ph.D.</u> Title: <u>Chief Scientific Officer</u>		

ASSIGNMENT

WHEREAS I, **AHMED HAMDY** of Santa Cruz, California hereinafter the “Assignor”, have made certain new and useful inventions as described in:

United States Patent Application No. 16/926,280, filed on July 10, 2020, entitled
“USE OF INHIBITORS OF BRUTONS TYRSINE KINASE (BTK)” {Atty. Docket
No. PIR-81970};

WHEREAS, Pharmacyclics LLC, a Limited Liability Company organized and existing under the laws of Delaware having a place of business at 1 N. Waukegan Road, North Chicago, IL 60064 hereinafter the “Assignee”, desires to acquire the entire right, title and interest in and to the inventions and the patent application(s) identified above, and all patents, foreign and domestic, which may be obtained for said inventions, and Assignor desires to assign such rights to Pharmacyclics LLC, as set forth below;

NOW, THEREFORE, in exchange for valuable and legally sufficient consideration, the receipt of which is hereby acknowledged:


1. The Assignor has sold, conveyed, assigned and transferred, and by these presents does sell, convey, assign and transfer, to the Assignee their entire right, title and interest for the United States and all other jurisdictions in and to the inventions and the patent application(s) identified above, and any patents that may issue for said inventions, together with all patent applications, patents, utility models and designs therefore, including without limitation all continuations, divisions, renewals, revivals, reissues, reexaminations, extensions, supplementary protection certificates, and any substitute applications thereof, including the full right to claim all benefits and priority rights thereto under any applicable convention or treaty including without limitation the Paris Convention, and all rights of action arising from the foregoing, including without limitation all claims for damages by reason of present, past and future infringement or violation of the foregoing and all present, past and future rights to sue and collect damages or seek injunctive relief for any such infringement or violation of the foregoing, in each case, to have and to hold for sole and exclusive use and benefit of the Assignee, its successors and assigns.

2. The Assignor hereby covenants and agrees that Assignor has the full right to convey the interests granted by this Assignment; and that the Assignor will assist the Assignee (including prompt production of pertinent facts and documents, giving of testimony, execution


of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by Assignee) in the prosecution of the patent applications identified above, in the making and prosecution of any other applications that the Assignee may elect to make covering the inventions identified above, in vesting in the Assignee with exclusive title in and to all such other patent applications and patents, in the prosecution of any interference which may arise involving said invention, or any such patent application or patent, and in assisting Assignee in the defense and enforcement of any rights arising out of such patent application or patent, or this Assignment; and that the Assignor will execute and deliver to the Assignee any and all additional papers which may be requested by the Assignee to carry out the terms of this Assignment.

3. The terms and covenants of this Assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor and their heirs, legal representatives and assigns.

IN WITNESS WHEREOF, the Assignor has executed this Assignment.

A handwritten signature in black ink, appearing to read 'Ahmed Hamdy', is written over a horizontal line.

Ahmed HAMDY

A handwritten date '5/21/24' is written in black ink over a horizontal line.

Date

Docket No.: PIR-81970
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 16/926,280
Filing Date: July 10, 2020
Patent No.: 11,672,803
First Inventor: Joseph J. BUGGY
Attorney No.: PIR-81970
Confirmation No.: 3851
Examiner: Ramachandran, Umamaheswari
For: USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)


STATEMENT TO CORRECT INVENTORSHIP UNDER 37 C.F.R. §1.324(b)(1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

I, **Joseph J. BUGGY**, the named inventor for U.S. Patent Number 11,672,803, hereby state that: (1) I agree to the correction of inventorship of the above-referenced patent through the addition of **Lee HONIGBERG**, **David J. LOURY**, and **Ahmed HAMDY** as co-inventors, as requested in the accompanying Request to Correct Inventorship; or (2) I have no disagreement in regard to the accompanying Request to Correct Inventorship.

DATED this 16th day of April, 2024

Signature: 

Printed Name: Joseph Buggy



ELECTRONIC PAYMENT RECEIPT

APPLICATION #
16/926,280

RECEIPT DATE / TIME
07/15/2024 07:06:24 PM Z ET

ATTORNEY DOCKET #
PIR-81970

Title of Invention

USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)

Application Information

APPLICATION TYPE Utility - Nonprovisional Application
under 35 USC 111(a)

PATENT # 11672803

CONFIRMATION # 3851

FILED BY Kathryn Dunn

PATENT CENTER # 66374725

AUTHORIZED BY Hathaway Russell

CUSTOMER # 136314

FILING DATE 07/10/2020

CORRESPONDENCE ADDRESS -

FIRST NAMED INVENTOR Joseph J. Buggy

Payment Information

PAYMENT METHOD
DA / 061448

PAYMENT TRANSACTION ID
E20247EJ07117028

PAYMENT AUTHORIZED BY
Hathaway Russell

PRE-AUTHORIZED ACCOUNT
061448

PRE-AUTHORIZED CATEGORY

37 CFR 1.16 (National application filing, search, and examination fees); 37 CFR 1.17 (Patent application and reexamination processing fees); 37 CFR 1.19 (Document supply fees); 37 CFR 1.20 (Post Issuance fees); 37 CFR 1.21 (Miscellaneous fees and charges)

FEE CODE	DESCRIPTION	ITEM PRICE(\$)	QUANTITY	ITEM TOTAL(\$)
1830	PROCESSING FEE, EXCEPT IN PROVISIONAL APPLICATIONS	140.00	1	140.00
1819	CORRECTION OF INVENTORSHIP AFTER FIRST ACTION ON MERITS	640.00	1	640.00
TOTAL AMOUNT:				\$780.00

by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.